ReviewAdvanced healthcare materials2023
Advances in Lipid-Based Codelivery Systems for Cancer and Inflammatory Diseases.
Review in Advanced healthcare materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 26 citations in OpenAlex.
- Targeting Osteosarcoma: The Dual Action of Halogenated Boroxine and Cerium Oxide Nanoparticles.International journal of molecular sciences · 2025Article
- Unlocking the full potential of piperine-loaded nanocarriers for cancer treatment.Therapeutic delivery · 2025Review
- An Overview on Lipid Nanocapsules: Exploring the Role in Precision Cancer Treatment and Lymphatic Drug Distribution.Advanced pharmaceutical bulletin · 2025Review
- Combination of miR159 Mimics and Irinotecan Utilizing Lipid Nanoparticles for Enhanced Treatment of Colorectal Cancer.Pharmaceutics · 2024Article
- Recent advances in drug delivery and targeting for the treatment of pancreatic cancer.Journal of controlled release : official journal of the Controlled Release Society · 2024Review
- Recent Progress in Nanotechnology Improving the Therapeutic Potential of Polyphenols for Cancer.Nutrients · 2023Review
- Nanotherapeutic Approaches to Treat COVID-19-Induced Pulmonary Fibrosis.Biotech (Basel (Switzerland)) · 2023Review
- Natural Compounds: Co-Delivery Strategies with Chemotherapeutic Agents or Nucleic Acids Using Lipid-Based Nanocarriers.Pharmaceutics · 2023Review
- Advances in Lipid-Based Codelivery Systems for Cancer and Inflammatory Diseases.Advanced healthcare materials · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Combination therapy targeting multiple therapeutic targets is a favorable strategy to achieve better therapeutic outcomes in cancer and inflammatory diseases. Codelivery is a subfield of drug delivery that aims to achieve combined delivery of diverse therapeutic cargoes within the same delivery system, thereby ensuring delivery to the same site and providing an opportunity to tailor the release kinetics as desired. Among the wide range of materials being investigated in the design of codelivery systems, lipids have stood out on account of their low toxicity, biocompatibility, and ease of formulation scale-up. This review highlights the advances of the last decade in lipid-based codelivery systems focusing on the codelivery of drug-drug, drug-nucleic acid, nucleic acid-nucleic acid, and protein therapeutic-based combinations for targeted therapy in cancer and inflammatory diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.